CDT CDT Equity Inc.
Listings ·
The November 12, 2026 meeting will vote on issuing stock under the Astor notes and warrants, and on reverse splits of up to 1-for-1,000. There were 9,322,805 shares outstanding on the October 23, 2026 record date.
The first tranche brought in $3,000,000, with net proceeds of $2,869,850 after closing fees. The lender can convert at 70% of the lowest recent close, with a floor of $0.18354, and the company reported $747,000 of cash at June 30, 2026.
The split takes effect September 28, 2026, to keep the company in compliance with the Nasdaq bid-price rule, and trading on the split-adjusted basis starts September 29.
The note matures March 1, 2027 and is payable in 24 weekly installments of $88,593.75. The lender can convert at the greater of 70% of the lowest volume-weighted average price or a $0.05 floor.
The note was issued on August 31, 2026 and repaid in full on September 4, 2026. It came with warrants for 237,000 shares.
CDT Equity and J.J. Astor & Co. signed a second amendment on July 31, 2026 that raised the note's principal to $2,266,650 at 19% interest. Weekly installments of $104,187.65 start August 19, 2026, and the lender may convert part of the balance into common stock.
The split takes effect July 17, 2026 and trades on a split-adjusted basis from July 20, reducing outstanding shares to approximately 631,077.
J.J. Astor & Co. is the lender on a senior secured convertible note with a principal amount of $1,971,000, amended on June 30, 2026. The company receives $1,460,000 in two tranches, and repays the loan in weekly installments of $82,125 starting July 10, 2026.
CDT Equity agreed to pay off its Alliance Global Partners and Ascent Partners loans and signed a loan of up to $1,460,000 with JJ Astor & Co, which it says is now its only loan facility. Its 2025 net loss was $39.2 million.
The company did not file its quarterly report for the period ended March 31, 2026 on time, and it has until July 20, 2026 to submit a plan to regain compliance.
The company says $0.4 million of milestone payments to Sarborg Limited were booked as research and development expense but should have been an acquired diagnostic asset. It plans to amend its first-quarter Form 10-Q.
The company reported pro forma stockholders' equity of $2.8 million as of March 31, 2025, against a $2.5 million minimum. It also said it meets the market value of publicly held securities rule.
Nasdaq's staff found on February 12, 2025 that Conduit Pharmaceuticals had not met two market value requirements within the 180-day grace period. The next day the company repaid the last $926,149 of a senior secured note to Nirland Limited, which it says was meant to help with the Nasdaq deficiencies.
CDT Equity Inc., formerly Conduit Pharmaceuticals Inc., describes itself as a data-driven pharmaceutical development company. It seeks to identify and advance clinical-stage compounds, particularly those deprioritized by larger pharmaceutical companies, using solid-form chemistry and co-crystallization at its Cambridge facilities to improve drug properties and extend patent life. Its pipeline targets autoimmune disorders, idiopathic male infertility, dermatology and animal health. The company holds a license from AstraZeneca covering the HK-4 Glucokinase Activator cocrystal AZD1656 and AZD5658 in all indications, and AZD5904 for idiopathic male infertility. A collaboration with Sarborg Limited applies AI-powered signature analysis to find new uses for existing compounds, and a partnership with Manoira Corporation extends the portfolio into animal health. The company says it intends to seek exits through third-party license deals after successful in vitro and in vivo preclinical studies.
| Product or program | What it is | Stage |
|---|---|---|
| AZD1656 cocrystal | Solid-form HK-4 Glucokinase Activator cocrystal for autoimmune disorders | pending patent applications; initial pre-clinical and clinical testing by AstraZeneca |
| AZD5904 | Myeloperoxidase inhibitor licensed for idiopathic male infertility | initial pre-clinical and clinical testing by AstraZeneca |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $5.1 million | $3.4 million |
| Net income (loss) | -$39.2 million | -$17.8 million |
| Cash from operations | -$15.6 million | -$9.7 million |
| Cash and equivalents | $1.5 million | $554,000 |
| Short-term investments | $600,000 |
Our latest story on this, dated Oct 27, 2026: "CDT Equity seeks votes on reverse splits up to 1-for-1,000 and Astor note shares". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Feb 19, 2025: "Conduit Pharmaceuticals (now CDT Equity) repays Nirland note as Nasdaq cites more delisting grounds". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 13, 2026: "CDT Equity gets $3,000,000 first tranche of $6,750,000 convertible note". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 28, 2026: "CDT Equity gets Nasdaq notice over late first-quarter 10-Q". The story links the filing or release it is based on. Read the story.
CDT Equity Inc. trades under the ticker CDT on NASDAQ.
CDT Equity Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for CDT Equity Inc. is 1896212. Its filings are on SEC EDGAR.
786,670 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-12.
Our directory records CDT Equity Inc. under United States.
Our directory classifies CDT Equity Inc. as: Mixed biopharma / AI and treasury. This is a directory classification, not a description of the pipeline.
The ISIN recorded for CDT Equity Inc. is US20678X7003.
aibio.space lists CDT Equity Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
CDT Equity Inc., formerly Conduit Pharmaceuticals Inc., describes itself as a data-driven pharmaceutical development company. It seeks to identify and advance clinical-stage compounds, particularly those deprioritized by larger pharmaceutical companies, using solid-form chemistry and co-crystallization at its Cambridge facilities to improve drug properties and extend patent life.
AZD1656 cocrystal: Solid-form HK-4 Glucokinase Activator cocrystal for autoimmune disorders Stage: pending patent applications; initial pre-clinical and clinical testing by AstraZeneca.
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 8.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 8-K (Items 3.02). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). Source
Said earlier financial statements should no longer be relied on. SEC Form 8-K (Items 4.02). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio